Sohrab P. Shah

Memorial Sloan Kettering Cancer Center — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

89h-index43.0kcitations607works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(157), Gastric Cancer Management and Outcomes(128), Esophageal Cancer Research and Treatment(113), Lymphoma Diagnosis and Treatment(109), Lung Cancer Treatments and Mutations(90)

Publications602 total

Enabling whole genome sequencing analysis from FFPE specimens in clinical oncology
Nature Communications·2025· 1 citedOpen Access
Supplementary Table S3 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Figure S7 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Figure S8 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Table S6 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Table S7 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Figure S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Table S5 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Figure S3 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Data S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Figure S4 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Table S2 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Methods S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Figure S9 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Figure S10 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Figure S6 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Figure S2 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Table S8 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Table S4 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Figure S5 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
page 1 of 31Next →

Frequent Co-authors

Samuel Aparício(25), Marco A. Marra(21), David G. Huntsman(20), Andrew McPherson(18), Ali Bashashati(14), Gavin Ha(13), Carlos Caldas(13), Andrew Roth(13), Leah Prentice(13), Karey Shumansky(13), Janine Senz(12), Richard A. Moore(12), Christian Steidl(11), Jiarui Ding(10), Steven J.M. Jones(10), Jessica N. McAlpine(10), Yongjun Zhao(9), Daniel Lai(9), Martin Hirst(9), Andrew J. Mungall(9)